Bristol-Myers Squibb Company announced consolidated unaudited earnings results for the fourth quarter and full year ended December 31, 2013. For the quarter, the company reported total revenues of $4,441 million against $4,191 million a year ago. Revenue was driven by higher sales for HIV drug Sustiva, hepatitis B treatment Baraclude and rheumatoid arthritis drug Orencia. Its top seller, schizophrenia drug Abilify, saw sales slip 22% to $635 million because of a renegotiated revenue-sharing deal with a partner. Earnings before income taxes were $869 million against $513 million a year ago. Net earnings were $735 million against $924 million a year ago. Net earnings attributable to company were $726 million against $925 million a year ago. Earnings per diluted common share were $0.44 against $0.56 a year ago. Non-GAAP net earnings attributable to company were $842 million against $777 million a year ago. Non-GAAP diluted earnings per common share were $0.51 against $0.47 a year ago. The company reported a 21.5% drop in its fourth-quarter profit despite higher drug sales, because the year-ago results had a $411 million tax benefit from writing off a failed experimental medicine.

For the full year, the company reported total revenues of $16,385 million against $17,621 million a year ago. Earnings before income taxes were $2,891 million against $2,340 million a year ago. Net earnings were $2,580 million against $2,501 million a year ago. Net earnings attributable to company were $2,563 million against $1,960 million a year ago. Earnings per diluted common share were $1.54 against $1.16 a year ago. Non-GAAP net earnings attributable to company were $3,019 million against $3,364 million a year ago. Non-GAAP diluted earnings per common share were $1.82 against $1.99 a year ago.

The company announced that setting its 2014 GAAP EPS guidance range from $1.75 to $1.90 and confirming its non-GAAP EPS guidance range from $1.65 to $1.80. Both GAAP and non-GAAP guidance assume current exchange rates and the closing of the sale of the diabetes business to AstraZeneca in the first quarter of 2014. The financial guidance for 2014 excludes the impact of any potential future strategic acquisitions and divestitures, and any specified items that have not yet been identified and quantified. The non-GAAP 2014 guidance also excludes other specified items as discussed under 'use of Non-GAAP Financial Information.